complement factor h การใช้

• Annexin A2 has been shown to interact with Prohibitin, CEACAM1, S100A10, PCNA and complement Factor H
• Shiga-toxin directly activates the alternative complement pathway and also interferes with complement regulation by binding to complement factor H, an inhibitor of the complement cascade.
• There are case reports of eculizumab being used to treat Shiga-toxin has been shown to trigger uncontrolled complement activity through direct activation of the alternative complement pathway as well as by binding to and inactivating the regulatory protein complement factor H.
• There are newer non-invasive urine bound markers available as aids in the diagnosis of bladder cancer, including human complement factor H-related protein, high-molecular-weight carcinoembryonic antigen, and nuclear matrix protein 22 ( NMP22 ).
• Polymorphisms of complement component 3, complement factor B, and complement factor I, as well as deletion of complement factor H-related 3 and complement factor H-related 1 also affect a person's risk of developing age-related macular degeneration.
• Polymorphisms of complement component 3, complement factor B, and complement factor I, as well as deletion of complement factor H-related 3 and complement factor H-related 1 also affect a person's risk of developing age-related macular degeneration.
• Complement factor H ( CFH ) is an important inhibitor of this inflammatory cascade, and a disease-associated polymorphism in the CFH gene strongly associates with AMD . Thus an AMD pathophysiological model of chronic low grade complement activation and inflammation in the macula has been advanced.
• Deletion of two adjacent genes with a high degree of homology to complement factor H, named complement factor H-related 3 and complement factor H-related 1, protects against age-related macular degeneration because of reduced competition for binding of CFH to vascular surface binding sites.
• Deletion of two adjacent genes with a high degree of homology to complement factor H, named complement factor H-related 3 and complement factor H-related 1, protects against age-related macular degeneration because of reduced competition for binding of CFH to vascular surface binding sites.
• Deletion of two adjacent genes with a high degree of homology to complement factor H, named complement factor H-related 3 and complement factor H-related 1, protects against age-related macular degeneration because of reduced competition for binding of CFH to vascular surface binding sites.
• These SNPs were located in the gene encoding complement factor H, which was an unexpected finding in the research of ARMD . The findings from these first GWA studies have subsequently prompted further functional research towards therapeutical manipulation of the complement system in ARMD . Another landmark publication in the history of GWA studies was the Wellcome Trust Case Control Consortium ( WTCCC ) study, the largest GWA study ever conducted at the time of its publication in 2007.